News
KPTI
5.89
+1.20%
0.07
Karyopharm Therapeutics Price Target Cut to $8.00/Share From $12.00 by Piper Sandler
Dow Jones · 5d ago
Piper Sandler Reiterates Overweight on Karyopharm Therapeutics, Lowers Price Target to $8
Benzinga · 5d ago
Piper Sandler Releases a Buy Rating on Karyopharm Therapeutics (KPTI)
TipRanks · 5d ago
Karyopharm price target lowered to $8 from $12 at Piper Sandler
TipRanks · 5d ago
Weekly Report: what happened at KPTI last week (0323-0327)?
Weekly Report · 5d ago
U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan
Reuters · 5d ago
KARYOPHARM THERAPEUTICS INC <KPTI.O>: PIPER SANDLER CUTS TARGET PRICE TO $8 FROM $12
Reuters · 5d ago
Karyopharm Strengthens Liquidity With New Equity Financing
TipRanks · 03/27 13:06
Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?
NASDAQ · 03/27 12:49
Karyopharm Therapeutics sells 1,030,354 shares at $6.785; gross proceeds rise to about $30 million in RA Capital private placement
Reuters · 03/27 12:05
Karyopharm: Putting The Phase 3 Trial In Context
Seeking Alpha · 03/26 11:01
Assertio (ASRT) Surges 17.9%: Is This an Indication of Further Gains?
NASDAQ · 03/25 12:35
Karyopharm Therapeutics Price Target Cut to $15.00/Share From $21.00 by Baird
Dow Jones · 03/25 12:32
Karyopharm Therapeutics Is Maintained at Outperform by Baird
Dow Jones · 03/25 12:32
Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $15
Benzinga · 03/25 12:22
BUZZ-Street View: Karyopharm's cancer drug trial results limit regulatory odds
Reuters · 03/25 11:49
Karyopharm price target lowered to $15 from $21 at Baird
TipRanks · 03/25 11:26
Karyopharm Therapeutics Price Target Cut to $8.00/Share From $15.00 by HC Wainwright & Co.
Dow Jones · 03/25 10:41
HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $8
Benzinga · 03/25 10:32
KARYOPHARM THERAPEUTICS, INC. <KPTI.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $8 FROM $15
Reuters · 03/25 10:11
More
Webull provides a variety of real-time KPTI stock news. You can receive the latest news about Karyopharm Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer. It is developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO is also marketed for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including myelofibrosis, endometrial cancer and multiple myeloma. The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.